Background/Aims: In addition to its cardiotonic effect, levosimendan has been thought to have multiple cardiovascular benefits, including anti-inflammatory and anti-apoptotic. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) has been revealed to be up-regulated in circumstances of coronary microembolization (CME), and the PTEN signaling pathway mediates myocardial apoptosis in swine after CME. However, whether this functional protein could be modified by pretreatment of levosimendan in models of CME has not been disclosed yet. Methods: Swine CME was induced by intra-coronary injection of inertia plastic microspheres (diameter 42μm) into left anterior descending coronary, with or without pretreatment of levosimendan or PTEN siRNA. Echocardiologic measurements, Terminal-deoxynucleotidyl Transferase Mediated Nick End Labeling (TUNEL) staining and western blotting were applied to assess their functional, morphological and molecular effects in CME. Results: PTEN mRNA and protein were aberrantly up-regulated in cardiomyocytes following CME. Furthermore, down-regulation of PTEN in vivo via siRNA was associated with an improved cardiac function, attenuated myocardial apoptosis, and concomitantly inhibited expressions of key proapoptotic proteins such as caspase-3. Interestingly, levosimendan could markedly attenuate PTEN expression and inhibit myocardial apoptosis, therefore partially reverse cardiac dysfunction. Conclusion: Modulation of PTEN was probably as a potential mechanism involved in the beneficial effects of pretreatment of levosimendan to cardiac function and apoptosis in animal models of CME.
Introduction
Coronary microembolization (CME), which can be induced by either a spontaneous rupture of a vulnerable coronary atherosclerotic plaque or therapeutic percutaneous (LAD) artery with the tip located between the second and third diagonal branches. Microspheres with a diameter of 42 μm (Dynospheres; Dyno Particles; Lillestrøm, Norway) at a mean dosage of 100,000 were selectively infused into the LAD within 40 min followed by a flush with 10 ml of saline. The sham-operated swine (sham group) were subjected to the same procedures, except that the injection was saline rather than microspheres. The systemic blood pressure and heart rate were continuously monitored during the procedure.
In vivo PTEN siRNA administration In vivo transfer was performed according to the method described previously [7] . After coronary angiography, a 1.8F infusion catheter (Cordis, Inc. USA) was placed in the LAD artery with the tip located between the second and third diagonal branches. A total of 100 μg of PTEN siRNA (Genepharma, PTENsus-368) or control siRNA (Genepharma) was diluted in the same volume of the in vivo transfection reagent (EntransterTM-in vivo; Engreen, Beijing, China). After mixing the solution gently by pipetting up and down, the siRNA solutions were selectively infused into the LAD. Then, 72 h after the PTEN siRNA or control siRNA administration, CME surgery was performed. In our previous study, we found that the protein level of PTEN was obviously up-regulated at 12h post-CME [5] , so all of the swine were sacrificed at 12 h after the CME or sham surgery in this study.
Design, synthesis and transfection of PTEN siRNA
The PTEN mRNA sequence was found in GenBank (Gene ID: 100156264) and synthesized by GenePharma company (Shanghai, China). The sense strand and the antisense strand of the PTEN siRNA were 5ˊ-GGCGUAUACAGGAACAAUATT-3ˊ and 5ˊ-UAUUGUUCCUGUAUACGCCTT -3ˊ, respectively. The control siRNA was purchased from the same company. A total mass of 100 μg PTEN siRNA or control siRNA was diluted with 100 μl transfection reagent (EntransterTM -in vivo; Engreen, Beijing, China). Mix thoroughly by pipetting the solution up and down. Then the mixture was injected intracoronarily via the 1.8 F infusion catheter, followed by 2 ml normal saline injection.
Serum c-troponin I measurement
EDTA-anticoagulated blood samples (1.0 ml) were collected from the femoral artery in each group 12 h following sham operation or CME and centrifuged at 4000 rpm for 15 min. Serum samples were stored at -80°C for detection. Serum c-troponin I was detected by electro-chemistry method according to the manufacturer's instruction (Roche, Inc, Switzerland).
Echocardiography
Transthoracic echocardiographic studies were performed by one experienced investigator who was blinded to the study protocol using a GE VIVID 7 system with a 1.5-4.3 MHZ transducer. Left ventricle ejection fraction (LVEF), left ventricle end-diastolic diameter (LVEDd), fractional shortening (FS) and cardiac output (CO) were obtained.
TUNEL assay
Apoptotic cardiomyocytes were detected using the terminal deoxymu-cleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay kit (Roche, USA). TUNEL-positive signal was located in nuclei and apoptotic nuclei were stained yellow-brown while the normal cell nuclei light blue. Meanwhile, morphological features of apoptosis (small, condensed nuclei, cell shrinkage and nuclear fragmentation) were taken into consideration. In each section, 10 random high-powered fields (magnification, ×400) were observed to count TUNEL-positive cardiomyocyte nuclei and apoptotic index (%) was calculated as the percentage ratio of TUNEL-positive cell nuclei to the total nuclei.
Real-time quantitative PCR analysis
Total RNA from a fresh tissue block was extracted using a Trizol Reagent Kit (Gibco, USA), and 4 μg of RNA was reverse-transcribed using a Reverse Transcriptase Kit (Promega, USA) according to the manufacturer's instructions.
Real-time PCR was performed using an ABI PRISM 7000 system (Applied Biosystems, CA, USA) using the non-sequence-specific SYBR Green I dye (TaKaRa, Japan). The reactions included 2 μl of cDNA, primers . The primers were 5-GAGCCATTTCCATCCTGCAG-3 and 5-GCTGTCATGTCTGGGAGTCT-3 for swine PTEN and 5-CACCTTCTACAACGAGCTGC-3 and 5-TCATCTTCTCACGGTTGGCT-3 for actin (all primers were designed by TaKaRa, Japan). The transcript expression levels were quantified via the Ct value method, and the Ct values were normalised to those of actin as an internal control in the same sample. The specificity of the amplified PCR products was confirmed based on the melting curves.
Western blot analysis
Briefly, myocardial tissues were homogenized, and aliquots of each fraction were used to determine the protein concentration of each sample using a detergent compatible assay. Protein samples (100 μg) were loaded onto polyacrylamide gel, electrophoresed, and transferred to a nitrocellulose membrane. The nitrocellulose membranes were then blocked followed by incubation with the primary antibodies overnight at 4°C. The following primary antibodies were purchased from Abcam: (1) rabbit anti-PTEN, (2) rabbit antiAkt, p-Akt (phosphorylation sites Threonine308), and (3) rabbit anti-cleaved caspase-3. Immunoblots were processed with secondary antibodies (Abcam Biotechnology) for 1 h at room temperature. Immunoblots were probed and then exposed to X-ray film. The X-ray films were scanned, and the optical density was determined by Bio-Rad image analysis (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Statistical analyses were performed using SPSS 13.0 statistical software (IBM Corporation, USA). The quantitative data are presented as the mean (SD). Unpaired Student's t-test and ANOVA were used for comparisons between two groups and among multiple groups, respectively, followed by the StudentNewman-Keuls test for the post hoc analysis. The P < 0.05 level indicated statistical significance.
Results

Animal groups
No significant differences in the body weight, blood pressure or heart rate were observed before and after operation among the four groups. However, after intravenous levosimendan pretreated porcine arterial blood pressure decreased significantly (Table 1) .
Levosimendan and PTEN siRNA pretreatments improved cardiac function following CME
Results of echocardiographic examination (Table 2) showed that 12 h after CME modeling, the CME group exhibited significantly decreased cardiac systolic function as Table 1 . Changes of heart rate, blood pressure and body weight before and after levosimendan -pretreatment among the four groups. CME, coronary microembolization; Sham indicates sham group; CME, CME group; Levo group, CME + Levo-pretreatment group. Data are presented as mean ± SD. a P < 0.05 compared with sham; b P < 0.05 compared with CME;
Levosimendan and PTEN siRNA pretreatments attenuated mocardial injury following CME Myocardial injury following CME could be assessed by levels of cTnI in the blood obtained from coronary sinus (Fig. 1) . At 12 h after CME modeling, serum level of cTnI in swine from CME group or control siRNA were higher than controls (0.228 ±0.030 μg/L vs 0.048 ± 0.008 μg/L, p < 0.05). Moreover, levosimendan pretreatment attenuated myocardial injury following CME, as reflected by the reduced cTnI levels in Levo group compared with CME group (0.122 ± 0.022 μg/L vs 0.228 ± 0.030 μg/L, p < 0.05). In addition, PTEN siRNA pretreatment was also associated with reduced cTnI levels (0.134 ± 0.014μg/L), which was similar to the effects of levosimendan pretreatment. No significant differences in the levels of cTnI was observed between the CME and Control siRNA groups (0.228 ± 0.030μg/L vs 0.219 ± 0.027 μg/L, p > 0.05).
Levosimendan and PTEN siRNA pretreatments decreased myocardial apoptosis following CME Myocardial apoptosis was assessed using TUNEL staining. Compared with the sham group, more TUNEL-positive (brown) cardiomyocytes could be detected in swine from the CME groups (P < 0.05). Interestingly, levosimendan treatment significantly decreased the relative proportion of apoptotic cells following CME (P < 0.05). The percentages of myocardial apoptotic cells in the sham, CME, Levo, and control siRNA were 0.24 ± 0.07, 10.56 ± 2.43, 6.82 ± 1.97 and 11.23 ± 2.65 respectively (Fig. 2) . In addition, PTEN siRNA pretreatment was Table 2 . Parameters of cardiac function in swine of each group 12 h after CME modeling: results of the Echocardiologic measurements. CME, coronary microembolization; LVEF, left ventricular ejection fraction; FS, fractional shortening; LVEDd, left ventricular end-diastolic diameter; CO, cardiac output; Levo, levosimendan; PTEN, phosphatase and tensin homolog deleted on chromosome ten. Data are presented as mean±SD.
a P < 0.05 compared with sham;
b P < 0.05 compared with CME or control siRNA (N = 5) Fig. 1 . Parameters of cTnI in swine of each group 12 h after CME modeling: CME, coronary microembolization; Levo, levosimendan; PTEN, phosphatase and tensin homolog deleted on chromosome ten. also associated with a decreased myocardial apoptosis (7.23 ± 1.85), similar to the effects of atorvastatin pretreatment.
The mRNA levels of PTEN each group
The PTEN mRNA expression was significantly higher in the CME and control siRNA groups than in the sham-operated group after surgery (12 h: 3.59 ± 0.98 and 3.47 ± 0.79 vs. 0.75 ± 0.15, p<0.05).The administration of PTEN siRNA and levosimendan reduced the mRNA level of PTEN to 1.78 ± 0.45 and 2.32 ± 0.84 (Fig. 3) .
PTEN siRNA pretreatment inhibited myocardial Akt signaling in CME swine
Western blotting showed significant up-regulation of PTEN and casepase-3 proteins, as well as a remarkable down-regulation of p-Akt, following CME modeling. Western blot analysis of the infarcted myocardial tissue in each group showed that the expressions of PTEN (Fig. 4A) , cleaved caspase-3 (Fig. 4C) were significantly increased in the myocardium of swine from CME groups compared with those from the sham group (P < 0.05). However, Fig. 2 . Representative images and quantitative analyses of myocardial apoptosis in minipigs from each group 12 h post CME modeling: results of the TUNEL staining. a, sham; b, PTEN siRNA; c, CME; d, control siRNA; e, Levo. Normal cell nuclei are stained in pale blue, while the apoptotic cardiomyocyte nuclei (arrows) are stained in brown (×200). Results of quantitative analyses indicated that the apoptotic indexes of myocardium were substantially lowered in Levo and PTEN siRNA groups as compared with the CME or the control siRNA groups (fig.2f ).
a p < 0.05 compared with CME or control siRNA. CME, coronary microembolization; Levo, levosimendan; PTEN, phosphatase and tensin homolog deleted on chromosome ten. Fig. 3 . The PTEN mRNA expression in swine of each group 12 h after CME modeling: CME, coronary microembolization; Levo, levosimendan; PTEN, phosphatase and tensin homolog deleted on chromosome ten. a P < 0.05 compared with sham;
b P < 0.05 compared with CME or control siRNA (N = 5).
Fig. 4.
Coronary microembolization (CME) induces cardiomyocyte apoptosis via the phosphatase and the tensin homolog deleted on chromosometen (PTEN)/Akt signaling pathway. The effects of CME and PTEN small-interfering RNA (siRNA) on the protein levels of PTEN and the Akt pathways as well as caspase 3 in the myocardial tissues in swine 12-hour post-CME modeling are as follows: the results of the Western blotting analyses. The expression levels of PTEN, cleaved caspase-3 were significantly increased in the CME group compared to those of the sham group (P < 0.05). The expression level of p-Akt (phosphorylation sitesThreonine308) was significantly decreased in the CME group compared to that of the sham group (P < 0.05). The expression levels of Akt and caspase-3 were not different among the sham, CME, and control siRNA groups. However, PTEN siRNA reduced the levels of PTEN and cleaved caspase-3 and enhanced the level of p-Akt compared to that of the CME group or the control siRNA group. These results indicate that CME induces cardiomyocyte apoptosis via the PTEN/Akt signaling pathway. a P < 0.05 versus sham; b P < 0.05 versus CME or control siRNA. N =Levosimendan pretreatment inhibited myocardial PTEN/Akt signaling following CME Western blot analysis of the infarcted myocardium in each group showed that the expressions of PTEN (Fig. 5A) , and cleaved caspase-3 ( Fig. 5C ) were significantly increased in the CME groups as compared with sham groups (P < 0.05). However, pretreatment of levosimendan reduced the levels of PTEN (Fig. 5A) , cleaved caspase-3 (Fig. 5C) proteins, but enhanced the levels of p-Akt (Fig. 5B) proteins as compared with CME group (P < 0.05). Western blot analysis of the infarcted myocardium in each group showed that the expressions of PTEN. Levosimendan could further inhibit the expression of PTEN protein. 5 . Effects of CME and Levo on the protein levels of PTEN, Akt pathways, caspase 3 in myocardial tissues in minipigs 12 h post CME modeling: results of western blotting analyses. The expression levels of PTEN (A) and cleaved-caspase-3 (C) were significantly increased in the CME group compared to those of the sham group (P < 0.05). The expression levels of p-Akt (B) was significantly decreased in the CME group compared to those of the sham group (P < 0.05). However, administration of levosimendan reduced the levels of PTEN, cleaved-caspase-3 proteins, and enhanced the levels of p-Akt proteins. a p < 0.05 versus sham; b P < 0.05 versus Levo. CME, coronary microembolization; PTEN, phosphatase and tensin homolog deleted on chromosome ten. Levo, levosimendan.
Discussion
Several novel findings of present study are summarized as followings. First, we demonstrated that levosimendan pretreatment was associated with attenuated myocardial apoptosis and therefore partially reversed the CME induced myocardial dysfunction. Second, the potential mechanisms underlying the protective effects of levosimendan against CME induced cardiac dysfunction may involve the regulation of PTEN/ Akt signaling pathway. Results of study highlighted the important role of PTEN/Akt in the pathogenesis of CME induced myocardial apoptosis. And, for the first time, our study suggested that levosimendan may attenuate CME induced cardiac dysfunction by modulation of PTEN/Akt pathway and proposed pretreatment of atorvastatin as a potential therapy for CME related cardiac dysfunction.
PTEN is the most common mutation of tumor suppressor gene. It has been recognized that the most important role of PTEN was to regulate normal developmental processes, including cell growth, adhesion, migration, invasion and apoptosis [18] . Recently, it has been showed that PTEN could be detected in vascular endothelial cells, vascular smooth muscle cells, cardiomyocytes and fibroblasts, and it also served as the key regulator of the pathogenesis of a variety of cardiovascular diseases, such as cardiac hypertrophy, myocardial contractile dysfunction, and cardiomyocytes apoptosis, probably by regulating downstream PI3K/Akt pathways [14, 19] . A variety of cytokines, growth factors and physical stimulation could activate PI3K so as to phosphorylate and activate Akt, which subsequently functions as a key factor in PI3K/Akt cell signaling pathways and downstream effecter of PI3K [20] . Activated Akt may exert its anti-apoptotic effect via regulation of caspase-3 [21] . Although early investigations suggested that activation of PI3K/Akt signaling pathway could effectively inhibit cardiomyocyte apoptosis and reduce the extent of myocardial injury [22] . In addition, by a series of tests, we have previously shown that PTEN/Akt pathway was activated in CME and involved in the pathogenesis of myocardial apoptosis [7, 15] .
Apoptosis, or programmed cell death, is the highly conserved and physiological process of eliminating cells in multicellular organisms. Apoptosis can be induced by many stimuli and includes the recruitment of caspases, which belong to the family of cysteine proteases. There are two major apoptotic pathways: Upon binding of Fas ligand (FasL) or other ligands to the Fas receptor on the cell surface, the extrinsic pathway involves cleavage of the initiator pro-caspase-8 into the active caspase-8 [23] . The intrinsic pathway is tightly regulated by proteins from the B-cell lymphoma (Bcl)-2 family [24] and targets the mitochondria: Antiapoptotic Bcl-2-like survival factors compete with pro-apoptotic Bax-like death factors [25] . Following the perforation of the outer mitochondrial membrane, cytochrome C and other 6 . The molecular cascade after coronary microembolization (CME) CME induced apoptosis via up-regulation of PTEN and reduced Akt and the modulation of other Akt-downstream apoptotic signals, such as caspase-3. After using PTEN siRNA or levosimendan, Akt and other downstream genes were affected, followed by the inhibition of the apoptotic cell death process. CME, coronary microembolization; PTEN, phosphatase and tensin homolog deleted on chromosome ten. Levo, levosimendan. proteins are released into the cytosol [26] resulting in cleavage of the initiator procaspase-9 into the active caspase-9. Ultimately, these two caspase cascades converge in cleaving procaspase-3 into the active effector caspase-3. Caspase-3 is the central apoptotic mediator and can be detected in cellular lysates [27] . Cells undergoing apoptotic death present a typical morphology, consisting of cell shrinking and nuclear fragmentation, which can be quantified in histopathological tissue sections by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling (TUNEL) staining [28] .
In addition to its cardiotonic effect, levosimendan has been thought to have multiple cardiovascular benefits, including anti-inflammatory and anti-apoptotic. Levosimendan has been developed for the treatment of acute heart failure and other cardiac conditions where the use of an inodilator is considered appropriate. The pharmacology of levosimendan includes positive inotropy with energy-sparing effects, positive effects on ventriculo-arterial coupling, peripheral vasodilation and increasing tissue perfusion, anti-stunning effects and anti-inflammatory and anti-apoptotic effects [9] . Levosimendan has been shown to protect cardiomyocytes from undergoing apoptosis, which depends on ATP-sensitive K+ channels [29] . Notably, in other tissues levosimendan can also show proapoptotic effects [30] . Experimental data focussing on levosimendan and apoptosis are not as abundant as in I/R injury. Pioneering in vitro work by Maytin et al. [10] showed that levosimendan, even at very low concentrations, protected cardiomyocyte from hydrogen peroxide-induced apoptosis by activating mito-chondrial ATP-dependent K+ channels. This effect was counteracted by the K+ channel inhibitor 5-hydroxydecanoid acid. Thus, a solid hypothesis of how levosimendan might influence I/R-induced cardiac apoptosis was provided [29] . Highly interesting in this context, althouth investigated in a considerably different experimental setting, is the observation that levosimendan and dextrosimendan, another simendan, can induce caspasedependent apoptosis (assessed by DNA fragmentation) [30] . The molecular mechanism was mediated by c-Jun NH2-terminal Kinase activation, but not by ATP-dependent K+ channels. In addition, Extracellular signal-Regulated Kinase and p38 Mitogen-Activated Kinase signalling pathways seemed to play no role in its action [30] . In a recently published study, 20 anesthetized (ketamine/pentobarbitone) and ventilated pigs underwent leftsided thoracotomy. The second branch of the LAD was obstructed by a tourniquet resulting in about 50% reduced poststenotic myocardial systolic shortening. Hypoperfusion was maintained for 4h. A bolus of 12μg/kg levosimendan was administered over 15min into the LAD proximal of the occluded branch. Levosimendan prevented the down-regulation of anti-apoptotic Bcl-2 and the release of cytochrome C from the mitochondria into the cytosol resulting in fewer fragmented nuclei in TUNEL staining [31] . In a study performed in anesthetized pigs, intracoronary levosimendan was able to protect heart against I/R by modulation of apoptosis and activation of RISK pathways (ERK1/2 and Akt) [32] . A role for mitoKATP channels and NO has been evidenced [33] . Similar anti-apoptotic effects have been found in liver and kidney, as well [34] .
We proved in a previous study that atorvastatin could inhibit myocardial apoptosis in a swine model of coronary microembolization by regulating PTEN/ Akt Signaling Pathway [7] . The potential regulatory effects of PTEN pathways could become a promising treatment strategy for CME related cardiac dysfunction in clinical scenarios. In this study, we found that levosimendan pretreatment could reduce CME-induced myocardial injury through inhibiting myocardial apoptosis with atorvastatin has a similar effect. Moreover, our study suggested again that regulation of PTEN/ Akt pathway seemed to be an important mechanism underlying the cardioprotective effects.
In conclusion, the potential therapeutic role of levosimendan seemed to be related to its regulatory effects on PTEN/ Akt pathway. However, it should be aware that our researches were performed in swine models and the findings may not be extrapolated directly to humans. Therefore, further researches, especially the translational research in humans are needed to evaluate whether the potential regulatory effects of levosimendan on PTEN pathways could become a promising treatment strategy for CME related cardiac dysfunction in clinical scenarios.
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